8-K: NanoViricides Amends At-the-Market Offering Agreement, Names EF Hutton as Sole Sales Agent

NanoViricides, Inc. has updated its at-the-market offering agreement, replacing B. Riley Securities with EF Hutton LLC as the sole sales agent for potential stock sales up to $50 million.

Summary

• NanoViricides, Inc. has entered into a new sales agreement with EF Hutton LLC, making them the sole sales agent for its at-the-market (ATM) offering.
• This agreement replaces the previous arrangement with both B. Riley Securities, Inc. and Kingswood Capital Markets (now EF Hutton LLC).
• The company may offer and sell shares of common stock from time to time through EF Hutton, with an aggregate offering price of up to $50 million.
• Sales will be made at the company's discretion, based on market conditions, stock price, and capital needs.
• NanoViricides is not obligated to sell any shares under this agreement.
• EF Hutton will receive a 3% commission on the gross sales price per share sold, plus reimbursement for certain legal expenses up to $50,000 for the agreement and $2,500 per quarter for ongoing legal fees.
• The shares will be sold under an existing shelf registration statement and related prospectus supplements.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It outlines a standard financial transaction that provides the company with a potential funding mechanism, but it does not guarantee any capital raise. The removal of one sales agent and replacement with another is not a significant event.

Positives

• The company has secured a sales agent to potentially raise capital through an at-the-market offering.
• The agreement provides flexibility for the company to sell shares based on market conditions and capital needs.

Negatives

• The company is not obligated to sell any shares, so there is no guarantee of capital being raised.
• The company will incur commission and legal expenses related to the sales.

Risks

• The company's ability to raise capital through this agreement depends on market conditions and the trading price of its stock.
• There is no guarantee that the company will be able to sell all or any of the $50 million in shares.
• The company will incur expenses regardless of whether shares are sold.

Future Outlook

The company may sell shares of common stock from time to time through EF Hutton, but there is no guarantee of any sales.

Management Comments

• The company will determine the timing and amount of sales based on market conditions, the trading price of the company's common stock, capital needs, and other factors.

Industry Context

At-the-market offerings are a common way for publicly traded companies, especially those in the biotech sector, to raise capital. This agreement allows NanoViricides to access funding as needed without a traditional underwritten offering.

Comparison to Industry Standards

• The 3% commission rate is within the typical range for at-the-market offerings.
• The use of a shelf registration statement is standard practice for this type of offering.
• Many biotech companies use ATM offerings to fund ongoing research and development activities.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The company may be able to fund its operations and research activities with the proceeds from the offering.
• The company's financial position may be strengthened if the offering is successful.

Next Steps

• The company may begin selling shares through EF Hutton at its discretion.
• The company will need to monitor market conditions and its capital needs to determine the timing and amount of sales.
• The company will need to file prospectus supplements with the SEC as sales occur.

Key Dates

Keywords

at-the-market offering, ATM, sales agreement, EF Hutton LLC, common stock, capital raise, placement shares, B. Riley Securities, securities, commission